WAVE Life Sciences Ltd (WVE) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ...

GuruFocus.com11-13

Revenue: Decreased from the prior year quarter due to onetime events in the Takeda collaboration and a noncash reduction under the GSK collaboration. Research and Development Expenses: $41.2 million ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2483576025?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/vlnKVzb3XyOK3rso_i_CnQ--~B/aD0zNjE7dz0zNjE7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/5c71844ecc7212c9a8bf717b74fd0d5d","is_english":true,"pubTime":"2024-11-13 15:08","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2483576025","market":"us","top_or_hot":-1,"title":"WAVE Life Sciences Ltd (WVE) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ...","media":"GuruFocus.com","content":"<div>\n<p>Revenue: Decreased from the prior year quarter due to onetime events in the Takeda collaboration and a noncash reduction under the GSK collaboration.\nResearch and Development Expenses: $41.2 million ...</p>\n\n<a href=\"https://finance.yahoo.com/news/wave-life-sciences-ltd-wve-070848419.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>WAVE Life Sciences Ltd (WVE) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ...</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWAVE Life Sciences Ltd (WVE) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ...\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-13 15:08 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/wave-life-sciences-ltd-wve-070848419.html><strong>GuruFocus.com</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Revenue: Decreased from the prior year quarter due to onetime events in the Takeda collaboration and a noncash reduction under the GSK collaboration.\nResearch and Development Expenses: $41.2 million ...</p>\n\n<a href=\"https://finance.yahoo.com/news/wave-life-sciences-ltd-wve-070848419.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"WVE","symbol_name":"Wave Life Sciences Pte. Ltd","start_time":0,"source_url":"https://finance.yahoo.com/news/wave-life-sciences-ltd-wve-070848419.html","article_id":"2483576025","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/vlnKVzb3XyOK3rso_i_CnQ--~B/aD0zNjE7dz0zNjE7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/5c71844ecc7212c9a8bf717b74fd0d5d"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2483576025","pubTimestamp":1731481728,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Revenue: Decreased from the prior year quarter due to onetime events in the Takeda collaboration and a noncash reduction under the GSK collaboration.Research and Development Expenses: $41.2 million for Q3 2024, up from $31.6 million in the prior year quarter.General and Administrative Expenses: $15 million for Q3 2024, compared to $13.1 million in the prior year quarter.Net Loss: $61.8 million for Q3 2024, compared to net income of $7.3 million in the prior year quarter.Cash and Cash Equivalents: $310.9 million at the end of Q3 2024, including $187.5 million from an upsized offering in September.Cash Runway: Sufficient to fund operations into 2027, excluding potential future milestone payments from the GSK collaboration.GuruFocus has detected 6 Warning Signs with WVE.For the complete transcript of the earnings call, please refer to the full earnings call transcript.WAVE Life Sciences Ltd  delivered three positive clinical data sets and received supportive initial feedback from the FDA ","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"WVE":"Wave Life Sciences Pte. Ltd","WAVE":"Eco Wave Power Global AB (publ)"},"translate_title":"WAVE Life Sciences Ltd(WVE)2024年第三季度收益看涨期权亮点：战略进展...","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"WAVE":1,"WVE":1},"content_text":"Revenue: Decreased from the prior year quarter due to onetime events in the Takeda collaboration and a noncash reduction under the GSK collaboration.\nResearch and Development Expenses: $41.2 million for Q3 2024, up from $31.6 million in the prior year quarter.\nGeneral and Administrative Expenses: $15 million for Q3 2024, compared to $13.1 million in the prior year quarter.\nNet Loss: $61.8 million for Q3 2024, compared to net income of $7.3 million in the prior year quarter.\nCash and Cash Equivalents: $310.9 million at the end of Q3 2024, including $187.5 million from an upsized offering in September.\nCash Runway: Sufficient to fund operations into 2027, excluding potential future milestone payments from the GSK collaboration.\n\n\nWarning! GuruFocus has detected 6 Warning Signs with WVE.\n\nRelease Date: November 12, 2024\nFor the complete transcript of the earnings call, please refer to the full earnings call transcript.\n Positive Points \n\nWAVE Life Sciences Ltd (NASDAQ:WVE) delivered three positive clinical data sets and received supportive initial feedback from the FDA on their Huntington's Disease (HD) program.\nThe company advanced its obesity program towards the clinic and strengthened its balance sheet to support its growing pipeline.\nWVE's RNA platform is consistently translating in the clinic, demonstrating the potential to design and advance first and best-in-class RNA medicines.\nThe company achieved a breakthrough in RNA medicine with the first-ever clinical demonstration of RNA editing in humans using their GalNAc-AIMer WVE-006.\nWVE-N531 in Duchenne Muscular Dystrophy (DMD) showed promising interim results, supporting it as a potential best-in-class treatment approach.\n\n Negative Points \n\nRevenue for the third quarter of 2024 decreased from the prior year due to one-time events in previous collaborations.\nResearch and development expenses increased significantly, driven by spending on multiple programs, leading to a net loss of $61.8 million for the quarter.\nThe company faces challenges in securing strategic partnerships, particularly for the HD program, which may impact the timeline for pivotal trials.\nThere is uncertainty regarding the FDA's full agreement on using caudate atrophy as an endpoint for potential accelerated approval in the HD program.\nThe company needs to manage the complexities of advancing multiple programs simultaneously, which could strain resources and focus.\n\n Q & A Highlights \nQ: Can you review the key efficacy assessments for the A1AT program in both lung and liver in the multi-dose cohorts? A: Anne-Marie Li-Kwai-Cheung, Chief Development Officer, explained that the RestorAATion-2 study is focused on safety, tolerability, pharmacodynamics, and pharmacokinetics, rather than efficacy outcomes in the lung or liver. Exploratory endpoints like FibroScan are included, but the primary focus is on safety and biomarkers.\nQ: Regarding the Huntington's program, what is the anticipated cost of the Phase II/III program, and what partnership structures are you considering? A: Paul Bolno, CEO, stated that they are in the planning phases of the study design, which will impact costs. They own the asset and have a clear clinical regulatory path, which are positive features for strategic partnerships. They are open to various partnership structures, including geographic and financial collaborations, to reduce costs and accelerate the asset.\nQ: How do you envision differentiating Inhibin E from GLP-1s in registration trials, especially concerning muscle mass loss? A: Paul Bolno highlighted that Inhibin E aims to achieve healthy, sustainable weight loss by reducing fat mass while retaining muscle mass, unlike GLP-1s. Preclinical data showed weight loss similar to GLP-1s but with increased muscle mass, which could differentiate Inhibin E in future trials.\nQ: Can you elaborate on the FDA's supportive stance regarding the Huntington's program and the timeline for the IND submission? A: Anne-Marie Li-Kwai-Cheung noted that the FDA is open to developing new biomarkers like caudate atrophy for accelerated approval. The IND submission is planned for the second half of 2025, considering the need for CMC and manufacturing work to support a potentially registrational study.\nQ: Are you considering running the pivotal Huntington's trial solo, or is finding a partner necessary? A: Paul Bolno mentioned that they are engaged in discussions with potential partners but emphasized that regulatory clarity and a clear clinical development path are crucial. They are exploring various partnership options but are prepared to advance the program independently if needed.\nFor the complete transcript of the earnings call, please refer to the full earnings call transcript.This article first appeared on \nGuruFocus.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2483576025"}